The clinical utility of prostate-specific antigen and bone scintigraphy in prostate cancer follow-up.
To assess the value of serum prostate-specific antigen (PSA) in prostate cancer follow-up, we prospectively studied 107 consecutive patients with: (1) pathologically confirmed prostate cancer; (2) definitive prostatectomy and/or radiation therapy greater than or equal to 3 mo prior to bone scanning; and (3) one bone scan and serum PSA sampling within 3 mo of each other. The mean and range of patient follow-up since definitive therapy was 1.6 and 0.5-8 yr, respectively. Abnormal bone scans were correlated with pertinent radiographs. Of 107 bone scans, 16 demonstrated metastatic bone disease. A PSA value of less than or equal to 8 ng/ml excluded bone metastases with a predictive value of a negative test of 98.5%. Without radiographic correlation, abnormal bone scans rarely represented metastases if the PSA value was less than or equal to 8 ng/ml. In summary, serum PSA concentration determines the need for follow-up bone scanning and assists in scan interpretation in patients status post definitive therapy for prostate cancer.
Freitas
J E
JE
William Beaumont Hospital, Royal Oak, Michigan.
Gilvydas
R
R
Ferry
J D
JD
Gonzalez
J A
JA
D000230:Adenocarcinoma / Q000097:blood / Q000453:epidemiology / Q000556:secondary*; D000951:Antigens, Neoplasm / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary*; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D011446:Prospective Studies; D017430:Prostate-Specific Antigen; D011471:Prostatic Neoplasms / Q000097:blood* / Q000453:epidemiology / Q000276:immunology; D011877:Radionuclide Imaging; D013669:Technetium Tc 99m Medronate
D000951:Antigens, Neoplasm; D014408:Biomarkers, Tumor; D017430:Prostate-Specific Antigen; D013669:Technetium Tc 99m Medronate